AnaptysBio
ANAB
52 hedge funds and large institutions have $328M invested in AnaptysBio in 2017 Q2 according to their latest regulatory filings, with 10 funds opening new positions, 23 increasing their positions, 12 reducing their positions, and 8 closing their positions.
92% more repeat investments, than reductions
Existing positions increased: 23 | Existing positions reduced: 12
25% more first-time investments, than exits
New positions opened: 10 | Existing positions closed: 8
4% more funds holding
Funds holding: 50 → 52 (+2)
0% more funds holding in top 10
Funds holding in top 10: 4 → 4 (0)
0.52% less ownership
Funds ownership: 68.13% → 67.61% (-0.52%)
14% less capital invested
Capital invested by funds: $382M → $328M (-$53.6M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Adage Capital Partners
Boston,
Massachusetts
|
+$7.2M |
| 2 |
AG
Artal Group
Luxembourg
|
+$5.16M |
| 3 |
PA
Perceptive Advisors
New York
|
+$1.77M |
| 4 |
BlackRock
New York
|
+$1.36M |
| 5 |
Northern Trust
Chicago,
Illinois
|
+$1.18M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DM
Deerfield Management
New York
|
-$7.36M |
| 2 |
IBT
International Biotechnology Trust
London,
United Kingdom
|
-$2.79M |
| 3 |
Millennium Management
New York
|
-$2.54M |
| 4 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
-$2.42M |
| 5 |
JP Morgan Chase
New York
|
-$2M |
ANAB Hedge Fund Activity: Q2 2017 in Review
52 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in AnaptysBio (ANAB) for Q2 2017, worth a combined $328M — down 14% from $382M a quarter earlier.
Buyers outnumbered sellers: 10 funds opened new ANAB positions and 8 closed out — a net gain of 2 holders — while 23 added to existing stakes and 12 trimmed.
The largest buyer was Adage Capital Partners, adding an estimated $7.2M. The largest seller was Deerfield Management, cutting an estimated $7.36M.
- 52 institutional investors held AnaptysBio (ANAB) as of Q2 2017, up from 50 in Q1 2017.
- Funds reported $328M of AnaptysBio stock for Q2 2017, down 14% quarter-over-quarter.
- 10 funds opened new AnaptysBio positions in Q2 2017 and 8 closed out, a net change of +2 holders.
- The largest AnaptysBio buyer in Q2 2017 was Adage Capital Partners, an estimated $7.2M added.
- The largest AnaptysBio seller in Q2 2017 was Deerfield Management, an estimated $7.36M sold.
Based on aggregated 13F filings for Q2 2017.